Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CANGRELOR for Thrombosis prophylaxis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 12 adverse event reports in the FDA FAERS database where CANGRELOR was used for Thrombosis prophylaxis.

Most Reported Side Effects for CANGRELOR

Side Effect Reports % Deaths Hosp.
Off label use 144 44.6% 25 9
Vascular stent thrombosis 29 9.0% 4 1
Drug ineffective 26 8.1% 3 13
Haemorrhage 22 6.8% 6 5
Death 19 5.9% 19 0
No adverse event 19 5.9% 0 0
Inappropriate schedule of product administration 18 5.6% 5 3
Cardiac arrest 15 4.6% 8 0
Cardiogenic shock 14 4.3% 11 3
Gastrointestinal haemorrhage 12 3.7% 2 6
Intentional product use issue 11 3.4% 1 1
Drug ineffective for unapproved indication 9 2.8% 2 0
Dyspnoea 9 2.8% 1 0
Haemorrhage intracranial 9 2.8% 3 2
Vascular access site haemorrhage 9 2.8% 3 1

Other Indications for CANGRELOR

Percutaneous coronary intervention (94) Product used for unknown indication (83) Off label use (81) Antiplatelet therapy (41) Acute myocardial infarction (17) Stent placement (15) Anticoagulant therapy (10) Coronary artery bypass (6)

Other Drugs Used for Thrombosis prophylaxis

RIVAROXABAN (27,466) APIXABAN (4,304) ENOXAPARIN (4,166) ASPIRIN (2,442) HEPARIN (1,633) CLOPIDOGREL BISULFATE (1,529) DABIGATRAN ETEXILATE (1,113) WARFARIN (959) TICAGRELOR (524) DALTEPARIN (519)

Related Pages

CANGRELOR Full Profile All Thrombosis prophylaxis Drugs CANGRELOR Demographics CANGRELOR Timeline